INTERPACE BIOSCIENCES, INC. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.

Public ticker
IDXG on OTC
Latest financial report
12 May 2026
Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Parsippany, NJ
SEC filing record 1 source field available
Fiscal year end
31 December

Shareable Research Card

IDXG - INTERPACE BIOSCIENCES, INC. Financial Facts

IDXG - INTERPACE BIOSCIENCES, INC. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.

Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.

Context
Latest metrics period: Q1 2026
Latest reported value
Return On Equity 210%

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Open stable link Open latest 10-Q/10-K hub Which companies report the highest revenue?

Return Loop

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q1 2026
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q1 2026.
  • Most recent SEC facts end date on this page: 31 Mar 2026.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Create account to save this filer Open latest 10-Q/10-K hub

Latest update

Latest update for IDXG - INTERPACE BIOSCIENCES, INC.

New fact period available

Latest financial period: Q1 2026. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

12 May 2026

Page type

Company facts

Latest period

Q1 2026

SEC-backed company facts were refreshed from filings filed on 12 May 2026.

Open recent updates hub Open latest 10-Q/10-K hub

Benchmark Context

How Return On Equity compares

Return On Equity is down about 861% versus the comparable prior period.

Compared with

Compared with INTERPACE BIOSCIENCES, INC.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.

Why this is notable

Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.

  • Latest comparable period on this page: Q1 2026.
  • Peer context will appear when enough companies report a comparable value for this metric.
  • Open the metric history first if you want to verify the exact period-to-period change.

Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.

Open Revenues YoY history Which companies report the highest revenue?

How to read key metrics on this page

These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.

Plain-English Guide

How to read Revenue on this page

Revenue is the sales a company reports from customers before most expenses are subtracted.

Why people care

People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.

How to read it

Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.

Compare next

Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.

Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.

Open a live SEC-backed example

Open Revenue guide

Plain-English Guide

How to read Net Income on this page

Net income is profit after operating costs, interest, taxes, and other non-operating items.

Why people care

It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.

How to read it

Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.

Compare next

Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.

Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.

Open a live SEC-backed example

Open Net Income guide

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it

Key facts

  • IDXG - INTERPACE BIOSCIENCES, INC. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q1 2026.
  • Headline metric: Return On Equity 210%.

Change

  • Return On Equity YoY change: -861%.
  • Most recent SEC facts end date: 31 Mar 2026.

Research use

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

View source filing

Latest SEC snapshot (2026-03-31) highlights Return On Equity 210.2%, Return On Assets 98.7%, and Operating Margin 9.3%.

Valuation Snapshot

Simple DCF estimate from SEC company facts, using free cash flow, cash, debt, and reported share count when available.

DCF value materially below price

-95%

fair value gap

Fair value per share

$0.1071

Market price

$1.96

IDXG - Local security

PEG ratio

0.1x

P/E 2.3x / growth 24%

EPS CAGR (3Y)

Enterprise value

$2.07M

Equity value

$2.97M

Key valuation metrics

EV/Revenue

1.5x

Local security market EV / SEC revenue

EV/EBITDA

15.3x

Local security market EV / SEC EBITDA

P/E

2.3x

Local security market price / SEC EPS

P/S

1.5x

Local security market cap / SEC revenue

P/B

2.4x

Local security market cap / SEC equity

PEG

0.1x

P/E / EPS CAGR

Core assumptions

Projection
5 years
FCF growth
4%
Discount rate
10%
Terminal growth
2.5%

SEC fact inputs

Free cash flow
$142K
Net income
$23.65M
EBITDA
$3.5M
Cash
$2.65M
Debt
$1.75M
Equity
$23.08M
Shares
27,707,000

Data confidence notes

No valuation input warnings from the current SEC fact snapshot.

Compare This Company Through SEC-backed Metrics

Use these links to compare IDXG - INTERPACE BIOSCIENCES, INC. against other SEC filers on the same metric, then verify the company history from the paired facts page.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

73.1/100

Balanced Confidence medium

Return On Equity

210%

Metric score 100.0/100

Return On Assets

99%

Metric score 100.0/100

Financial Health

Current Ratio
2.51x
Quick Ratio
2.16x

Strengths

Return On Equity, Return On Assets, and Current Ratio

Watchpoints

Operating Margin and Revenues YoY

Key metrics snapshot

Profitability

Metric Latest value YoY change
Return On Equity 210% -861%
Return On Assets 99% +72%
Operating Margin 9.3% -49%

Financial Health

Metric Latest value YoY change
Current Ratio 2.51x +87%
Quick Ratio 2.16x +88%

Growth

Metric Latest value YoY change
Revenues YoY -25%
NetIncomeLoss YoY 210%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 27,700,904 +526%
Common Stock, Shares, Outstanding 27,700,904 +526%
Common Stock, Value, Issued $640,000 +57%
Weighted Average Number of Shares Outstanding, Basic 22,786,000 +416%
Weighted Average Number of Shares Outstanding, Diluted 27,707,000 +0.01%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY change
Accounts Payable, Current $805,000 -54%
Accounts Receivable, after Allowance for Credit Loss, Current $5,925,000 -32%
Assets $33,409,000 +131%
Assets, Current $9,963,000 -15%
Cash and Cash Equivalents, at Carrying Value $2,647,000 +121%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,647,000 +121%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $142,000
Common Stock, Par or Stated Value Per Share 0.01 0%
Common Stock, Shares Authorized 100,000,000 0%
Common Stock, Shares, Issued 27,844,994 +511%
Cost of Revenue $13,581,000 -21%
Deferred Income Tax Assets, Net $20,977,000
Deferred Income Taxes and Tax Credits $277,000
Depreciation, Depletion and Amortization $118,000 +24%
Earnings Per Share, Basic 5.21 +220%
Earnings Per Share, Diluted 0.86 +187%
Employee-related Liabilities, Current $714,000 -61%
General and Administrative Expense $9,381,000 -4.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $3,135,000 -60%
Income Tax Expense (Benefit) $302,000 +1578%
Increase (Decrease) in Accounts Receivable $276,000 +23%
Inventory, Net $961,000 -21%
Lessee, Operating Lease, Liability, to be Paid $1,237,000 -31%
Lessee, Operating Lease, Liability, to be Paid, Year One $550,000 0%
Lessee, Operating Lease, Liability, to be Paid, Year Two $275,000 -50%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $157,000 -50%
Liabilities $10,327,000 -32%
Liabilities and Equity $33,409,000 +131%
Liabilities, Current $3,962,000 -54%
Net Cash Provided by (Used in) Investing Activities $141,000
Net Cash Provided by (Used in) Operating Activities $283,000 -77%
Operating Income (Loss) $3,378,000 -62%
Operating Lease, Liability $1,080,000 -27%
Operating Lease, Liability, Current $445,000 +13%
Operating Lease, Liability, Noncurrent $635,000 -41%
Operating Lease, Right-of-Use Asset $1,110,000 -27%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 0%
Other Assets, Current $1,391,000 -18%
Other Assets, Noncurrent $44,000 -2.2%
Other Liabilities, Noncurrent $5,730,000 +7.7%
Payments to Acquire Property, Plant, and Equipment $141,000
Preferred Stock, Par or Stated Value Per Share 0.01 0%
Preferred Stock, Shares Authorized 5,000,000 0%
Property, Plant and Equipment, Net $1,315,000 +3%
Research and Development Expense $618,000 -14%
Retained Earnings (Accumulated Deficit) $210,084,000 +10%
Revenue from Contract with Customer, Excluding Assessed Tax $36,245,000 -25%
Selling and Marketing Expense $9,287,000 -20%
Share-based Payment Arrangement, Noncash Expense $4,000 -73%
Stockholders' Equity Attributable to Parent $23,082,000

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .